Larimar Therapeutics, Inc. (LRMR) 8-K Current Report — March 9, 2026

Filed: March 9, 2026

Health Care

Pharmaceutical Preparations

Larimar Therapeutics, Inc. (LRMR) 8-K current report filed with SEC EDGAR on March 9, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

Item 8.01: Other Events

Larimar Therapeutics, Inc. 8-K Mar 9, 2026 Event Analysis

Item 8.01 · Other Events

• Updated investor slide deck posted March 9, 2026, to be used in ongoing meetings with investors and analysts
• Substantive content in Exhibit 99.1 — presentation likely contains pipeline/clinical updates for Larimar's lead program (nomlabofusp for Friedreich's ataxia)

Other Larimar Therapeutics, Inc. 8-K Filings

8-K Mar 19, 2026

8-K Feb 27, 2026

8-K Feb 24, 2026

Get deeper insights on Larimar Therapeutics, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.